Company / Operating Margin
Sunshine Biopharma Inc. Operating Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-16.7%
FY2025
5-year range
-1068.2% / -16.7%
FY2021-FY2025
Trend
+16.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Margin has increased for 3 consecutive years, from -1068.2% in FY2022 to -16.7% in FY2025.
Based on SEC 10-K filings.
-16.7% in FY2025 with a 5-year CAGR of +3021.2%.
Improved from -621.3% to -16.7% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- +1051.6pp
- 5-Year Change
- +3021.2pp
- 10-Year Change
- -
Key checks
Key Insights
- Sunshine Biopharma Inc.'s operating margin has grown for 3 consecutive years.
- In FY2025, operating margin increased 16.1% year-over-year.
- Lowest operating margin in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -16.7% | +16.1% |
| FY2024 | -19.9% | +96.8% |
| FY2023 | -621.3% | +41.8% |
| FY2022 | -1068.2% | -32.2% |
| FY2021 | -807.8% | +73.4% |
| FY2020 | -3037.9% | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | -45683.7% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026